AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL ...Middle East

Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3...

Hence then, the article about amgen s repatha cuts risk of first major adverse cardiovascular events by 25 in landmark phase 3 vesalius cv trial was published today ( Saturday 08/11/2025 - 06:24 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL )

Also on site :

• Katie Couric Shares Photo From Hospital Bed With Important PSA: 'Wish Me Luck'
• Russia-Ukraine war: List of key events, day 1,428
• Thrash Metal Icon Reveals Truth About Final Album of 43-Year-Old Band